Lv1
38 积分 2023-08-25 加入
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study
1个月前
已完结
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
6个月前
已完结
Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling
8个月前
已完结
Resistance to Bruton Tyrosine Kinase Inhibitors
10个月前
已完结
Bruton's tyrosine kinase (BTK) inhibitors: an updated patent review (2019-2024)
10个月前
已完结
Exploiting PubChem and other public databases for virtual screening in 2025: what are the latest trends?
1年前
已完结
皖公网安备34019202002308
